The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marme F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching P, Lux MP, Lueftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H (2019)


Publication Type: Journal article

Publication year: 2019

Journal

Book Volume: 14

DOI: 10.1016/j.jbo.2018.09.010

Abstract

Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase IIIb 4EVER study.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Hadji, P., Stoetzer, O., Decker, T., Kurbacher, C.M., Marme, F., Schneeweiss, A.,... Tesch, H. (2019). The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. Journal of Bone Oncology, 14. https://dx.doi.org/10.1016/j.jbo.2018.09.010

MLA:

Hadji, Peyman, et al. "The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial." Journal of Bone Oncology 14 (2019).

BibTeX: Download